🔗 Share this article

Government ministers and leading parliamentarians have issued warnings that the United Kingdom's recent agreements with the US administration are "built on sand." This stems from revelations that a much-touted deal on pharmaceutical tariffs, which commits to zero tariffs in exchange for the NHS increasing its costs, lacks any underlying contract beyond vague headline terms published in government press releases.

A Deal Without Detail

The arrangement concerning medicines, hailed as a "significant" achievement, is still an "agreement in principle" without detailed provisions. It has been highlighted that the public statements from the UK and US governments frame the deal in sharply different terms. The British version emphasizes securing "zero per cent tariffs" as a singular success, while the American announcement highlights the agreement for the NHS to pay 25% more for new medications.

"There is a serious risk that the UK government has made commitments to increase medicine costs in return for little more than a assurance from President Trump," said David Henig, a trade policy analyst. "It is documented he has a record of not keeping promises."

A Pattern of Unreliability

Anxieties have been heightened by Washington's recent decision to suspend the high-value digital accord, which was previously heralded as "a generational step-change" in the bilateral relationship. The US claimed a lack of progress from the UK on reducing other tariffs as the reason for the pause.

In a separate development, concessions secured for British farmers as part of an May trade agreement have still not been formally signed off by the US, despite a imminent January deadline. "It is our belief that the US has not yet signed off the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

In confidential discussions, ministers have voiced worries that the government's US-UK accords are flimsy and unreliable. One minister described the series of agreements as "resting on shaky ground," while another framed the situation as the "new normal" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, a senior MP on the health committee, stated: "The only thing more surprising than Trump's temper tantrums is the UK government's credulous faith that his administration is a reliable partner. The NHS is not a bargaining chip."

Government Downplays Risks, Points to Gains

Officials have downplayed the risk of the US reneging on the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been pushing for the agreement, seeking certainty on imports and pricing, making it more concrete than the paused tech deal.

Officials concede that unpredictability is inherent in dealing with the current US leadership. However, they argue that the UK has secured concrete outcomes for businesses, such as reduced duties on automobiles compared to other nations. "Securing 25% steel tariffs, which is better than the rate for the rest of the world, is not flimsy," one official said.

However, problems have surfaced in enacting the May tariff agreement. Promised reciprocal agricultural allowances have yet to be finalized, and the commitment to "eliminate duties on UK metals" has remains unmet, with tariffs remaining at 25%.

Looking ahead, the two sides have agreed to resume talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.